Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Liabilities (2017 - 2026)

Denali Therapeutics has reported Total Liabilities over the past 9 years, most recently at $131.1 million for Q4 2025.

  • Quarterly Total Liabilities fell 9.28% to $131.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.1 million through Dec 2025, down 9.28% year-over-year, with the annual reading at $131.1 million for FY2025, 9.28% down from the prior year.
  • Total Liabilities was $131.1 million for Q4 2025 at Denali Therapeutics, up from $129.4 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $442.6 million in Q1 2023 and troughed at $115.5 million in Q2 2024.
  • The 5-year median for Total Liabilities is $146.6 million (2024), against an average of $263.8 million.
  • Year-over-year, Total Liabilities skyrocketed 201.1% in 2021 and then tumbled 71.62% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $441.9 million in 2021, then dropped by 5.44% to $417.8 million in 2022, then plummeted by 70.57% to $123.0 million in 2023, then rose by 17.51% to $144.5 million in 2024, then decreased by 9.28% to $131.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Total Liabilities are $131.1 million (Q4 2025), $129.4 million (Q3 2025), and $139.2 million (Q2 2025).